Get started
Author

John Carl Pesko

Observed names: J Pesko, J. Pesko, John C Pesko, John C. Pesko, John Pesko
ORCID: 0000-0002-7568-7762
Observed ORCID: 0000-0002-7568-7762
OpenAlex ID: A5072013221
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2021 · Vinod A. Pullarkat, Norman J. Lacayo, et al. · Cancer Discovery · 302
Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
2020 · Jonathan L. Kaufman, Cristina Gasparetto, et al. · American Journal of Hematology · 109
PDF
Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study
2020 · Sven de Vos, John P. Leonard, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 95
PDF
Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction
2018 · Limor Raz, Kiran Bhaskar, et al. · Neurobiology of Disease · 84
Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
2021 · Matthew S. Davids, Andrew W. Roberts, et al. · Clinical Cancer Research · 73
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
2021 · Shuo Ma, John F. Seymour, et al. · Blood · 45
Biomarkers identify the Binswanger type of vascular cognitive impairment
2018 · Erik Barry Erhardt, John C Pesko, et al. · Journal of Cerebral Blood Flow & Metabolism · 25
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
2018 · Luciano J. Costa, Edward Allen Stadtmauer, et al. · Journal of Clinical Oncology · 21
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
2021 · Relja Popovic, Fengjiao Dunbar, et al. · American Journal of Hematology · 20
PDF
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
2019 · Jonathan L. Kaufman, Cristina Gasparetto, et al. · Blood · 19
Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2018 · Luciano J Costa, Edward A. Stadtmauer, et al. · Blood · 18
Improving Depth of Thinking in Online Discussion Boards.
2015 · Sheri S. Williams, Amy Jaramillo, et al. · 18
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial
2021 · Tara Cochrane, Alicia Enrico, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 17
PDF
Parametric boostrap and objective Bayesian testing for heteroscedastic one-way ANOVA
2021 · Guoyi Zhang, Ronald Christensen, et al. · Statistics & Probability Letters · 14
ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia
2021 · Matthew S. Davids, Kirsten Fischer, et al. · Blood · 13
MMP-9 inhibitors impair learning in spontaneously hypertensive rats
2018 · Limor Raz, Yi Yang, et al. · PLoS ONE · 12
PDF
First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
2019 · Nizar Bahlis, Rachid Baz, et al. · Blood · 10
Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2020 · Jeffrey E. Rubnitz, Thomas B. Alexander, et al. · Blood · 7
Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome
2026 · Fumihiko Urano, Bess A. Marshall, et al. · Journal of Clinical Investigation · 3
PDF
Posterior brain sensorimotor recruitment for inhibition of delayed responses in children
2021 · Kristina T. R. Ciesielski, Christopher Bouchard, et al. · Experimental Brain Research · 2
Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study
2020 · Ian W. Flinn, David Andorsky, et al. · Blood · 2
Ps1375 Updated Safety and Efficacy From a Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients With Relapsed/refractory Multiple Myeloma
2019 · L. Costa, E. Stadtmauer, et al. · HemaSphere · 2
Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study
2021 · Ian W. Flinn, David Andorsky, et al. · Blood · 1
CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia
2020 · Jeff Sharman, David Andorsky, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
2018 · Orlando Bueno, Rachel Slimp, et al. · Journal of Clinical Oncology · 1
Works count: 40
Citation count: 912
H-index: 14
I10-index: 17
Year
Topic
Type